Company Description
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases.
Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials.
The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection.
Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016.
Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
| Country | United States |
| Founded | 2006 |
| IPO Date | Jul 31, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 121 |
| CEO | Dr. Laurent Fischer |
Contact Details
Address: 100 Cardinal Way Redwood City, California 94063 United States | |
| Phone | (650) 649-1004 |
| Website | adverum.com |
Stock Details
| Ticker Symbol | ADVM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001501756 |
| CUSIP Number | 00773U108 |
| ISIN Number | US00773U1088 |
| Employer ID | 20-5258327 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Laurent Fischer | President, Chief Executive Officer and Director |
| Linda M. Rubinstein M.A. | Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer |
| Kishor Peter Soparkar J.D. | Chief Operating Officer |
| Dr. Setareh Seyedkazemi Pharm.D. | Chief Development Officer |
| Dr. R. Andrew Ramelmeier Ph.D. | Chief Technology Officer |
| Dr. Romuald Corbau Ph.D. | Chief Scientific Officer |
| John W. Rakow J.D. | Senior Vice President and General Counsel |
| Dena House | Chief People Officer |
| Carla Fiankan | Senior Vice President of Regulatory Affairs |
| Michael Steel | Senior Vice President of Quality |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 17, 2024 | 8-K | Current Report |
| Jun 28, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 18, 2024 | 8-K | Current Report |
| Jun 11, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 11, 2024 | 8-K | Current Report |
| May 28, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 14, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| May 9, 2024 | 10-Q | Quarterly Report |
| May 9, 2024 | 8-K | Current Report |
| May 2, 2024 | ARS | Filing |